Sei Investments Co. Sells 4,131 Shares of argenex SE $ARGX

Sei Investments Co. cut its position in shares of argenex SE (NASDAQ:ARGX) by 1.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 312,268 shares of the company’s stock after selling 4,131 shares during the quarter. Sei Investments Co. owned approximately 0.51% of argenex worth $230,318,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in argenex by 59.8% in the third quarter. BNP Paribas Financial Markets now owns 106,714 shares of the company’s stock worth $78,708,000 after buying an additional 39,919 shares in the last quarter. Sands Capital Management LLC bought a new position in argenex during the third quarter valued at approximately $12,262,000. Mackenzie Financial Corp raised its stake in shares of argenex by 55.8% during the third quarter. Mackenzie Financial Corp now owns 4,135 shares of the company’s stock worth $3,050,000 after acquiring an additional 1,481 shares in the last quarter. Capital World Investors raised its stake in shares of argenex by 0.4% during the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares in the last quarter. Finally, Capital International Sarl bought a new stake in shares of argenex in the 3rd quarter worth approximately $1,364,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Stock Down 2.6%

Shares of NASDAQ ARGX opened at $708.85 on Friday. The firm’s fifty day moving average is $806.79 and its 200 day moving average is $815.81. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The company has a market cap of $43.86 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 1.20 and a beta of 0.38.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating the consensus estimate of $6.05 by $1.97. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a net margin of 30.42% and a return on equity of 38.51%. Equities research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ARGX shares. Royal Bank Of Canada cut their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Morgan Stanley lifted their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 4th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. HC Wainwright raised their price objective on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, DZ Bank upgraded argenex to a “strong-buy” rating in a report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and an average target price of $999.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.